AllianceBernstein’s Neuropace NPCE Stock Holding History

AllianceBernstein’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,310	Closed	-$117K	–	3278
2025 Q3	$117K	Hold	11,310	–	–	﹤0.01%	3169
2025 Q2	$126K	Buy	+11,310	New	+$141K	﹤0.01%	3139

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AllianceBernstein's NPCE Position: Q4 2025 in Review

AllianceBernstein sold out of Neuropace (NPCE) in Q4 2025, closing a stake of 11,310 shares — an estimated $117K sold.

AllianceBernstein first reported a position in NPCE in Q2 2025 and held it in 2 quarters. The position peaked at $126K in Q2 2025. 100 funds tracked by Wall St. Rank hold NPCE as of Q4 2025.

AllianceBernstein reported no remaining Neuropace position as of Q4 2025 after selling out during the quarter.
AllianceBernstein sold 11,310 Neuropace shares in Q4 2025, an estimated $117K.
AllianceBernstein first reported a position in Neuropace in Q2 2025 and held it in 2 quarters.
AllianceBernstein's Neuropace position peaked at $126K in Q2 2025.
100 funds tracked by Wall St. Rank held Neuropace as of Q4 2025.

Based on AllianceBernstein's 13F filing for Q4 2025, filed 17 Feb 2026.